(VIANEWS) – The Market ended the session with MITHRA (MITRA.BR) rising 9.18% to €3.81 on Thursday while BEL 20 fell 0.69% to €3,822.72.
MITHRA’s last close was €3.49, 78.72% under its 52-week high of €16.38.
About MITHRA
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Earnings Per Share
As for profitability, MITHRA has a trailing twelve months EPS of €-2.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -138.93%.
Yearly Top and Bottom Value
MITHRA’s stock is valued at €3.81 at 21:36 EST, way under its 52-week high of €16.38 and way higher than its 52-week low of €2.28.
Revenue Growth
Year-on-year quarterly revenue growth declined by 6.5%, now sitting on 21.88M for the twelve trailing months.
Moving Average
MITHRA’s worth is way above its 50-day moving average of €3.11 and way under its 200-day moving average of €5.57.
More news about MITHRA (MITRA.BR).
